OCUP - Ocuphire announces peer-reviewed publication of Phase 2 results for Nyxol

Ocuphire Pharma (OCUP) announced that results from its ORION-1 (NCT03960866) Phase 2 clinical trial evaluating the safety and efficacy of Nyxol® in glaucoma and presbyopia have been published in the peer-reviewed, open access journal, Clinical Ophthalmology.Key findings from the double-masked, randomized, placebo-controlled, multiple-dose, multi-center trial include a statistically significant 20% mean reduction or ~1 mm in pupil diameter under daytime and nighttime lighting conditions that was sustained for over 30 hours post-dosing with Nyxol eye drops.Over 60% of patients in the Nyxol treatment group have shown a statistically significant improvement of 1-line or greater in near visual acuity compared to 20% on placebo. There was no statistical difference in eye redness compared to placebo upon examination in the following morning after dosing in the prior evening before bedtime.“We are excited to announce the second peer-reviewed publication of clinical results from our second recent Phase 2 trial in our Nyxol program,” says Mina Sooch, President/CEO

For further details see:

Ocuphire announces peer-reviewed publication of Phase 2 results for Nyxol